Editas Deal Opens Allergan's Eyes To CRISPR Opportunities
Executive Summary
Editas' stock shot up 11% by mid-morning on March 14, after the gene therapy company announced a deal with Allergan worth $90m up front for "cool" CRISPR programs in ocular indications. However, the lead therapy included in the deal offers potentially limited profitability in a small orphan space.
You may also be interested in...
Deals Of The Year: Cast Your Vote For Top Alliance Of 2017
It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.
Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.